Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Equity Bottom-Up

<ul><li>Looking ahead in 2025, we expect greater visibility in Ainos’ AI Nose programs, including robotics, smart manufacturing, elderly care monitoring, and Ainos Flora for women’s health testing.</li><li>Veldona clinical trials in Sjogren’s syndrome and HIV-related oral warts remain on track, with Taiwan study completions expected in 2026.</li><li>Sets eye on robotics. Ainos aims to expand its AI Nose application to robotics. It is seeking collaboration with the robotics and humanoid developers, as it believes now is the time to equip robotics with the ability to smell, filling a key gap in robot sensory capabilities.</li></ul>

Looking ahead in 2025, we expect greater visibility in Ainos’ AI Nose programs, including robotics, smart manufacturing, elderly care monitoring, and Ainos Flora for women’s health testing.Veldona clinical trials in Sjogren’s syndrome and HIV-related oral warts remain on track, with Taiwan study completions expected in 2026.Sets eye on robotics. Ainos aims to expand its AI Nose application to robotics. It is seeking collaboration with the robotics and humanoid developers, as it believes now is the time to equip robotics with the ability to smell, filling a key gap in robot sensory capabilities.

Ainos, Inc: Previewing the Year Ahead with Focus on AI Nose Programs

<ul><li>Key regional partner for Veldona; a good start for Ainos’ out-licensing strategy.</li><li>Ainos entered a strategic partnership with Taiwan Tanabe Seiyaku for Veldona in Sjogren’s syndrome.</li><li>Under a memorandum of understanding (MOU), the collaboration aims to advance Veldona development by leveraging Taiwan Tanabe’s established expertise in drug manufacturing and Taiwan market promotion. </li></ul>

Key regional partner for Veldona; a good start for Ainos’ out-licensing strategy.Ainos entered a strategic partnership with Taiwan Tanabe Seiyaku for Veldona in Sjogren’s syndrome.Under a memorandum of understanding (MOU), the collaboration aims to advance Veldona development by leveraging Taiwan Tanabe’s established expertise in drug manufacturing and Taiwan market promotion. 

Ainos, Inc.- Signed Veldona Partner for Manufacturing and Taiwan Marketing of Sjogren's Drug

<ul><li>Clinical site IRB approval for Veldona Sjogren’s trial. Ainos received Institutional Review Board (IRB) approval from the Shuang Ho Hospital (Taipei Medical University) to conduct the Veldona clinical study in primary Sjogren’s syndrome.</li><li>TFDA approval is expected next quarter, with the site initiation visit to start around April 2025.</li><li>Ainos expects study completion in December 2026.</li></ul>

Clinical site IRB approval for Veldona Sjogren’s trial. Ainos received Institutional Review Board (IRB) approval from the Shuang Ho Hospital (Taipei Medical University) to conduct the Veldona clinical study in primary Sjogren’s syndrome.TFDA approval is expected next quarter, with the site initiation visit to start around April 2025.Ainos expects study completion in December 2026.

Ainos, Inc.: IRB Approval for Veldona Sjogren's Trial

<ul><li>Jack Lu, Director of Corporate Development, joined us on the WTR Small-Cap Spotlight podcast to discuss Veldona, Ainos’ clinical stage low-dose interferon-α (IFN-α)  therapeutic.</li><li>We covered Veldona’s clinical history, therapeutic effects, disease priorities, market opportunity, and timelines for clinical studies.</li><li>Those interested can listen to this podcast on Apple Podcasts, Spotify, or on our website.</li></ul>

Jack Lu, Director of Corporate Development, joined us on the WTR Small-Cap Spotlight podcast to discuss Veldona, Ainos’ clinical stage low-dose interferon-α (IFN-α)  therapeutic.We covered Veldona’s clinical history, therapeutic effects, disease priorities, market opportunity, and timelines for clinical studies.Those interested can listen to this podcast on Apple Podcasts, Spotify, or on our website.

Ainos, Inc: WTR Small-Cap Spotlight Recap - Veldona Drug Platform and Clinical Studies

<ul><li>Taiwan Veldona human study to start in Sjogren’s.</li><li>Ainos will initiate a Veldona clinical study in Taiwan for primary Sjogren’s syndrome in December 2024.</li><li>This follows the announcement of an oral warts in HIV+ clinical study planned for November 2024. </li></ul>

Taiwan Veldona human study to start in Sjogren’s.Ainos will initiate a Veldona clinical study in Taiwan for primary Sjogren’s syndrome in December 2024.This follows the announcement of an oral warts in HIV+ clinical study planned for November 2024. 

Ainos, Inc. - Veldona Sjogren's Study Start to Quickly Follow Oral Warts

United States

Ainos, Inc. is a diversified healthcare company. The Company engages in the discovery and development of novel biopharmaceuticals, technologically medical treatments, and consumer products, as well as provides treatments of neoplastic, viral, and autoimmune diseases. Ainos operates in the United States and Taiwan.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ainos (AIMD US)

Ainos, Inc: Previewing the Year Ahead with Focus on AI Nose Programs

Looking ahead in 2025, we expect greater visibility in Ainos’ AI Nose programs, including robotics, smart manufacturing, elderly care monitoring,...

Water Tower Research

Ainos, Inc.- Signed Veldona Partner for Manufacturing and Taiwan Marketing of Sjogren's Drug

Key regional partner for Veldona; a good start for Ainos’ out-licensing strategy. Ainos entered a strategic partnership with Taiwan Tanabe Seiyaku...

Water Tower Research

Ainos, Inc.: IRB Approval for Veldona Sjogren's Trial

Ainos received Institutional Review Board (IRB) approval from the Shuang Ho Hospital (Taipei Medical University) to conduct the Veldona clinical...

Water Tower Research

Ainos, Inc: WTR Small-Cap Spotlight Recap - Veldona Drug Platform and Clinical Studies

Jack Lu, Director of Corporate Development, joined us on the WTR Small-Cap Spotlight podcast to discuss Veldona, Ainos’ clinical stage low-dose...

Water Tower Research

Ainos, Inc. - Veldona Sjogren's Study Start to Quickly Follow Oral Warts

Taiwan Veldona human study to start in Sjogren’s. Ainos will initiate a Veldona clinical study in Taiwan for primary Sjogren’s syndrome in December...

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)